A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
It is proposed that postural and spinal assessment, along with ergonomic assessments, should be considered, based on the observation that addressing these factors has been found to improve comfort in some studies, although experimental data are lacking, and the perceived benefits may not be specific to those interventions. A 2010 survey by NIOSH showed that two-thirds of the 5 million carpal tunnel diagnoses in the US that year were related to work. Women are more likely to be diagnosed with work-related carpal tunnel syndrome than men. Many if not most patients described in published series of carpal tunnel release are older and often not working. Normal pressure of the carpal tunnel has been defined as a range of 2–10 mm (0.079–0.394 in). Wrist flexion increases the pressure eight-fold and extension increases it ten-fold. There is speculation that repetitive flexion and extension in the wrist can cause thickening of the synovial tissue that lines the tendons within the carpal tunnel.
== Safety == Dimethylformamide vapor exposure has shown reduced alcohol tolerance and skin irritation in some cases. On 20 June 2018, the Danish Environmental Protective Agency published an article about DMF's use in squishies. The density of the compound in the toy resulted in all squishies being removed from the Danish market. All squishies were recommended to be thrown out as household waste.
Zooarchaeology by mass spectrometry, commonly referred to by the abbreviation ZooMS, is a scientific method that identifies animal species by means of characteristic peptide sequences in the protein collagen. ZooMS is the most common archaeological application of peptide mass fingerprinting (PMF) and can be used for species identification of bones, teeth, skin and antler. It is commonly used to identify objects that cannot be identified morphologically. In an archaeological context this usually means that the object is too fragmented or that it has been shaped into an artefact. Archaeologists use these species identification to study among others past environments, diet and raw material selection for the production of tools.
== Chemistry == Mirtazapine is a tetracyclic piperazinoazepine; mianserin was developed by the same team of organic chemists and mirtazapine differs from it via the addition of a nitrogen atom in one of the rings. It is a racemic mixture of enantiomers. The (S)-(+)-enantiomer is known as esmirtazapine. Analogues of mirtazapine include mianserin, setiptiline, and aptazapine.
The French naturalist Georges-Louis Leclerc (1707–1788) underlined the benefits of donkey milk in his Histoire Naturelle. Some effects have been supported by systematic and scientific studies starting from the mid-1800s, especially by Russian doctors. Donkey and mare's milk are very similar, and it is assumed they have similar properties. The beneficial effects of equid milk, from the first historical sources to the present day, are aimed at:
Sources: en.wikipedia.org
On 16 May 2023, three weeks after Tangaraju was put to death, 36-year-old Muhammad Faizal Mohd Shariff, a Singaporean who was found guilty in 2019 of trafficking 1.5 kg of marijuana was reported to have lost his final appeal to commute his sentence. A day after losing his appeal, Muhammad Faizal was hanged at dawn on 17 May 2023, with the authorities confirming his execution despite not naming Muhammad Faizal out of consideration for his family's need for privacy. Two executions of a 56-year-old man and 45-year-old woman (both convicted of drug offences) were scheduled to take place on 26 July and 28 July 2023 respectively; the female offender Saridewi Djamani was believed to be the first woman to be executed in 19 years, as the last known execution of a woman took place on 19 March 2004, when 37-year-old Yen May Woen was put to death for diamorphine trafficking. The 56-year-old male drug offender Mohd Aziz Hussain, as well as Saridewi, were both hanged as scheduled, becoming the third and fourth persons respectively to be executed in Singapore in the year of 2023. On 3 August 2023, Singapore carried out the hanging of Mohamed Shalleh Abdul Latiff, a 39-year-old Singaporean and former delivery driver found guilty of trafficking 54.04g of diamorphine in 2016. In total, five executions, all once again for drug trafficking, took place in the year 2023. When 35-year-old Ahmed Salim was hanged on 28 February 2024 for murdering his former fiancée, he was the first criminal hanged in Singapore in that year.
===== Sleep disorder in Alzheimer's disease ===== Studies have shown that daytime and evening light therapy for nursing home patients with Alzheimer's disease, who often struggle with agitation and fragmented wake/rest cycles effectively led to more consolidated sleep and an increase in circadian rhythm stability.
== Overview == Trails is a series of role-playing video games by Nihon Falcom set in a science fantasy universe. It began as the sixth entry in Falcom's The Legend of Heroes franchise with the release of The Legend of Heroes VI: Trails in the Sky in 2004. Despite that, it had no narrative connection with prior Legend of Heroes games and is considered its own distinct franchise. The Trails games are set within a few years of each other and follow an overarching narrative, with the events of a few entries crossing over into another. The series was conceived by Falcom to have the most ambitious story in video games, with company president and series producer Toshihiro Kondo considering it to be his life's work. The games are made using a proprietary game engine known as the Falcom Developer Kit (FDK), with the exception being Sony's PhyreEngine used for the Trails of Cold Steel games and Trails into Reverie. The series is heavily influenced by anime and features several archetypes and tropes common to it. Trails is set across several locations on the continent of Zemuria, such as the Liberl Kingdom, the city-state of Crossbell, the Erebonian Empire, and the Calvard Republic, among others. Zemuria is home to several groups, factions, and organizations, such as the Bracer's Guild, the Septian Church, the secret society of Ouroboros, mercenary groups known as Jaegers, and several more. The series is set half a century after the discovery of orbal energy, an analog to electric power.
== Research and applications == Since matrikine peptides are used primarily for cosmetic applications which require only limited safety testing and have no requirement for proof of efficacy, much research into these peptides has been published in self-published sources such as patent applications, or in open-access journals which are generally regarded as low-quality sources due to the limited scope of peer review. This has meant that the claimed skin repair and anti-aging efficacy of these peptides has historically been treated with skepticism by the mainstream scientific community and regarded as marketing hype which has not been proven by rigorous scientific research. In recent years however, increasing evidence has accumulated to support the claimed activity of at least some of the matrikine peptides, along with investigation of these molecules for potential clinical applications such as treatment of arthritis and tendinopathy, and this has led medicines regulators in some jurisdictions such as Australia and New Zealand to view certain peptides from this group as medicines, and consequently ban them by classifying them as prescription medicines which are not actually available for prescription. In most parts of the world however these peptides are still classified as cosmetics and can be sold with relatively few restrictions, and they are widely used in countries such as Japan, China, South Korea, the United States and in Europe.
== Toxicity == Upon binding, the toxin is suggested to induce a prolonged sensation of severe pain, accompanied with neurogenic inflammation due to enduring TRPV1 activation. However, specific behavioural effects remain unknown. In line with the isolated toxin effect, the toxic effects of the crude venom are reported to be mainly nociceptive and inflammatory, but not lethal.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.